image
XOMA Corporation XOMAP
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 26.0771
1.03 %
$ 352 M
Market Cap
26.05
P/E
1. INTRINSIC VALUE

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.[ Read More ]

The intrinsic value of one XOMAP stock under the base case scenario is HIDDEN Compared to the current market price of 26.1 USD, XOMA Corporation is HIDDEN

XOMAP Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart XOMAP

image
FINANCIALS
4.76 M REVENUE
-21.06%
Growth Rates
1Year -21.06%
3Years -45.50%
5Years -2.13%
7Years -2.21%
10Years -18.20%
-41.8 M OPERATING INCOME
-140.31%
Growth Rates
1Year -140.31%
3Years -63.50%
5Years -19.94%
7Years 5.36%
10Years 3.25%
-40.8 M NET INCOME
-138.72%
Growth Rates
1Year -138.72%
3Years -59.67%
5Years -25.07%
7Years 3.79%
10Years 10.52%
-18.2 M OPERATING CASH FLOW
-40.99%
Growth Rates
1Year -40.99%
3Years -40.93%
5Years -7.51%
7Years 8.45%
10Years 8.86%
-711 K INVESTING CASH FLOW
96.48%
Growth Rates
1Year 96.48%
3Years -50.40%
5Years 45.66%
7Years -11.64%
10Years -0.37%
121 M FINANCING CASH FLOW
2809.35%
Growth Rates
1Year 2809.35%
3Years 82.64%
5Years 32.13%
7Years 52.71%
10Years 3.76%
7.2 M REVENUE
-35.08%
Growth Rates
1Year -21.06%
3Years -45.50%
5Years -2.13%
7Years -2.21%
10Years -18.20%
-15.6 M OPERATING INCOME
-1349.49%
Growth Rates
1Year -140.31%
3Years -63.50%
5Years -19.94%
7Years 5.36%
10Years 3.25%
-17.2 M NET INCOME
-107.87%
Growth Rates
1Year -138.72%
3Years -59.67%
5Years -25.07%
7Years 3.79%
10Years 10.52%
-8.62 M OPERATING CASH FLOW
-325.84%
Growth Rates
1Year -40.99%
3Years -40.93%
5Years -7.51%
7Years 8.45%
10Years 8.86%
0 INVESTING CASH FLOW
0.00%
Growth Rates
1Year 96.48%
3Years -50.40%
5Years 45.66%
7Years -11.64%
10Years -0.37%
-4 M FINANCING CASH FLOW
-290.72%
Growth Rates
1Year 2809.35%
3Years 82.64%
5Years 32.13%
7Years 52.71%
10Years 3.76%
Balance Sheet Decomposition XOMA Corporation
image
Current Assets 169 M
Cash & Short-Term Investments 153 M
Receivables 15.2 M
Other Current Assets 643 K
Non-Current Assets 65 M
Long-Term Investments 0
PP&E 403 K
Other Non-Current Assets 64.6 M
Current Liabilities 19.5 M
Accounts Payable 653 K
Short-Term Debt 5.65 M
Other Current Liabilities 13.2 M
Non-Current Liabilities 126 M
Long-Term Debt 119 M
Other Non-Current Liabilities 7.23 M
EFFICIENCY
Earnings Waterfall XOMA Corporation
image
Revenue 4.76 M
Cost Of Revenue 897 K
Gross Profit 3.86 M
Operating Expenses 46.5 M
Operating Income -41.8 M
Other Expenses -1.02 M
Net Income -40.8 M
RATIOS
81.15% GROSS MARGIN
81.15%
Averages
1Year 81.15%
3Years 93.03%
5Years 94.34%
7Years 89.29%
10Years 70.63%
-879.53% OPERATING MARGIN
-879.53%
Averages
1Year -879.53%
3Years -374.18%
5Years -220.28%
7Years -198.17%
10Years -299.90%
-858.15% NET MARGIN
-858.15%
Averages
1Year -858.15%
3Years -366.85%
5Years -219.44%
7Years -188.76%
10Years -252.36%
-46.02% ROE
-46.02%
Averages
1Year -46.02%
3Years -16.23%
5Years -10.16%
7Years 18.63%
10Years -9.97%
-17.43% ROA
-17.43%
Averages
1Year -17.43%
3Years -6.71%
5Years -3.51%
7Years -0.86%
10Years -26.29%
-19.66% ROIC
-19.66%
Averages
1Year -19.66%
3Years -7.14%
5Years -5.62%
7Years 0.92%
10Years 132.38%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis XOMA Corporation
image
Net Income -40.8 M
Depreciation & Amortization 900 K
Capital Expenditures -17 K
Stock-Based Compensation 9.1 M
Change in Working Capital -3.53 M
Others 13.2 M
Free Cash Flow -18.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets XOMA Corporation
image
XOMAP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.44% DIVIDEND YIELD
0.539 USD DIVIDEND PER SHARE
5. COMPETITION

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health.

image
-2.05 USD
XOMAO
Overvalued 108.06%

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.

image
-0.161 USD
FBIOP
Overvalued 103.16%

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to health plans and other third-party payors in the United States.

image
-0.767 USD
OTRKP
Overvalued 379.78%

B. Riley Financial, Inc., through its subsidiaries, provides investment banking and financial services to corporate, institutional, and high net worth clients in North America, Australia, and Europe.

image
8.55 USD
RILYP
Undervalued 12.59%
6. Ownership
Insider Ownership XOMA Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Oct 03, 2023
Bought 3.47 K USD
Sitko Bradley
Chief Investment Officer
+ 250
 13.89 USD
1 year ago
Oct 02, 2023
Bought 21.4 K USD
Sitko Bradley
Chief Investment Officer
+ 1500
 14.25 USD
1 year ago
Oct 02, 2023
Bought 13.8 K USD
Hughes Owen
Exec Chairman and Interim CEO
+ 1000
 13.83 USD
1 year ago
Sep 26, 2023
Bought 36.1 K USD
Hughes Owen
Exec Chairman and Interim CEO
+ 2499
 14.43 USD
1 year ago
Sep 25, 2023
Bought 14.7 USD
Hughes Owen
Exec Chairman and Interim CEO
+ 1
 14.65 USD
1 year ago
May 31, 2023
Bought 17.2 K USD
Sitko Bradley
Chief Investment Officer
+ 1000
 17.2 USD
1 year ago
May 31, 2023
Bought 8.5 K USD
Sitko Bradley
Chief Investment Officer
+ 500
 17 USD
1 year ago
May 23, 2023
Bought 16.2 K USD
Sitko Bradley
Chief Investment Officer
+ 850
 19 USD
1 year ago
May 24, 2023
Bought 24.6 K USD
Hughes Owen
Interim CEO
+ 1032
 23.79 USD
1 year ago
May 23, 2023
Bought 18 K USD
Hughes Owen
Interim CEO
+ 768
 23.49 USD
1 year ago
May 23, 2023
Bought 4.67 K USD
Hughes Owen
Interim CEO
+ 200
 23.33 USD
1 year ago
May 19, 2023
Bought 19.5 K USD
Sitko Bradley
Chief Investment Officer
+ 1000
 19.5 USD
1 year ago
May 16, 2023
Bought 2.32 K USD
Sitko Bradley
Chief Investment Officer
+ 100
 23.25 USD
1 year ago
May 16, 2023
Bought 2.32 K USD
Sitko Bradley
Chief Investment Officer
+ 100
 23.2 USD
1 year ago
May 16, 2023
Bought 6.96 K USD
Sitko Bradley
Chief Investment Officer
+ 300
 23.19 USD
1 year ago
May 12, 2023
Bought 37.2 K USD
Sitko Bradley
Chief Investment Officer
+ 1957
 19 USD
1 year ago
May 15, 2023
Bought 35.1 K USD
Sitko Bradley
Chief Investment Officer
+ 1500
 23.4 USD
1 year ago
May 12, 2023
Bought 802 USD
Sitko Bradley
Chief Investment Officer
+ 43
 18.66 USD
1 year ago
Jan 06, 2023
Bought 36.8 K USD
BVF PARTNERS L P/IL
Director
+ 1676
 21.9817 USD
1 year ago
Jan 05, 2023
Bought 61.2 K USD
BVF PARTNERS L P/IL
Director
+ 3330
 18.3852 USD
1 year ago
Jan 06, 2023
Bought 34.6 K USD
BVF PARTNERS L P/IL
Director
+ 1573
 21.9817 USD
1 year ago
Jan 05, 2023
Bought 288 K USD
BVF PARTNERS L P/IL
Director
+ 15670
 18.3852 USD
2 years ago
Sep 27, 2022
Bought 17 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 1004
 16.8902 USD
2 years ago
Sep 26, 2022
Bought 56.2 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 3339
 16.8317 USD
2 years ago
Sep 23, 2022
Bought 111 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 6715
 16.497 USD
2 years ago
Sep 27, 2022
Bought 11.5 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 678
 16.8902 USD
2 years ago
Sep 26, 2022
Bought 50.8 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 3021
 16.8317 USD
2 years ago
Sep 23, 2022
Bought 163 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 9885
 16.497 USD
2 years ago
Sep 16, 2022
Bought 240 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 13396
 17.8873 USD
2 years ago
Sep 16, 2022
Bought 195 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 10897
 17.8873 USD
2 years ago
Sep 15, 2022
Bought 100 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 5575
 17.962 USD
2 years ago
Sep 14, 2022
Bought 456 K USD
BVF PARTNERS L P/IL
director, 10 percent owner:
+ 26441
 17.2476 USD
3 years ago
Dec 11, 2020
Bought 5 M USD
BVF PARTNERS L P/IL
Director
+ 200000
 25 USD
4 years ago
Dec 18, 2019
Bought 4.56 M USD
BVF PARTNERS L P/IL
Director
+ 207234
 22 USD
4 years ago
Dec 18, 2019
Bought 3.65 M USD
BVF PARTNERS L P/IL
Director
+ 165961
 22 USD
6 years ago
Nov 19, 2018
Bought 375 K USD
BVF PARTNERS L P/IL
Director
+ 25000
 14.9957 USD
6 years ago
Nov 19, 2018
Bought 513 K USD
BVF PARTNERS L P/IL
Director
+ 37482
 13.6786 USD
6 years ago
Nov 19, 2018
Bought 136 K USD
BVF PARTNERS L P/IL
Director
+ 9771
 13.9253 USD
6 years ago
Apr 26, 2018
Sell 382 K USD
Neal James R
CEO
- 15655
 24.4162 USD
7 years ago
Dec 21, 2016
Sell 77.9 K USD
Varian John
Director
- 13549
 5.75 USD
8 years ago
Nov 01, 2016
Sell 788 USD
Neal James R
VP Business Development
- 150
 5.25 USD
7. News
8. Profile Summary

XOMA Corporation XOMAP

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 352 M
Dividend Yield 0.44%
Description XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Contact 2200 Powell Street, EmeryVille, CA, 94608 https://www.xoma.com
IPO Date Dec. 16, 2020
Employees 13
Officers Mr. Owen P. Hughes Jr. Chief Executive Officer & Director Mr. Thomas M. Burns Senior Vice President of Finance & Chief Financial Officer Mr. Brad Sitko Chief Investment Officer